Marie Thibault
Stock Analyst at BTIG
(4.10)
# 479
Out of 4,945 analysts
76
Total ratings
56.94%
Success rate
11.19%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Buy | $148 → $145 | $129.28 | +12.16% | 12 | Jul 18, 2025 | |
| ATRC AtriCure | Maintains: Buy | $58 → $52 | $35.40 | +46.89% | 7 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $120 → $124 | $104.15 | +19.06% | 10 | Apr 23, 2025 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $2.66 | +351.13% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $13.87 | +87.45% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $315.78 | -14.50% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $151.87 | +11.94% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $38.03 | +70.92% | 8 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $52.33 | +114.03% | 1 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $79.96 | +50.08% | 7 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.32 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.45 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $10.47 | +91.02% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $162.44 | -13.81% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.46 | +379.45% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.56 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.48 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $226.74 | -97.35% | 1 | Apr 9, 2020 |
Abbott Laboratories
Jul 18, 2025
Maintains: Buy
Price Target: $148 → $145
Current: $129.28
Upside: +12.16%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $58 → $52
Current: $35.40
Upside: +46.89%
Boston Scientific
Apr 23, 2025
Maintains: Buy
Price Target: $120 → $124
Current: $104.15
Upside: +19.06%
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $2.66
Upside: +351.13%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $13.87
Upside: +87.45%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $315.78
Upside: -14.50%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $151.87
Upside: +11.94%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $38.03
Upside: +70.92%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $52.33
Upside: +114.03%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $79.96
Upside: +50.08%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.32
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.45
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $10.47
Upside: +91.02%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $162.44
Upside: -13.81%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.46
Upside: +379.45%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.56
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.48
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $226.74
Upside: -97.35%